John Weiland - West Pharmaceutical Independent Director
| WST Stock | USD 385.73 4.47 1.15% |
Director
Mr. John H. Weiland is no longer Independent Director of West Pharmaceutical Services, Inc., effective May 7, 2019. Mr. Weiland served as President and Chief Operating Officer of C. R. Bard, Inc. a medicaldevice company from August 2003 to December 2017, when Bard was acquired by Becton, Dickinson and Company. In connection with that acquisition, Mr. Weiland retired. At Bard, he served as Group President from April 1997 to August 2003 and Group Vice President from March 1996 to April 1997 since 2007.
| Age | 61 |
| Tenure | 17 years |
| Address | 530 Herman O. West Drive, Exton, PA, United States, 19341-1147 |
| Phone | 610 594 2900 |
| Web | https://www.westpharma.com |
West Pharmaceutical Management Efficiency
The company has Return on Asset of 0.1193 % which means that on every $100 spent on assets, it made $0.1193 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2132 %, implying that it generated $0.2132 on every 100 dollars invested. West Pharmaceutical's management efficiency ratios could be used to measure how well West Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.17 in 2024. Return On Capital Employed is likely to gain to 0.22 in 2024. At this time, West Pharmaceutical's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 4 B in 2024, despite the fact that Change To Liabilities is likely to grow to (3.1 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Charles Dockendorff | Haemonetics | 66 | |
| Agnes Lee | ResMed Inc | N/A | |
| Marshall Larsen | Becton Dickinson and | 72 | |
| Thomas Ryan | Repligen | 75 | |
| Jan Witte | ResMed Inc | 56 | |
| Luis Huete | Alcon AG | N/A | |
| David Melcher | Becton Dickinson and | 66 | |
| Chris Roberts | ResMed Inc | 61 | |
| Gary Mecklenburg | Becton Dickinson and | 70 | |
| Ronald Merriman | Haemonetics | 72 | |
| Thomas Bahen | Alcon AG | N/A | |
| Ludwig Hantson | Hologic | 55 | |
| Nancy Leaming | Hologic | 67 | |
| Stanley Zinberg | The Cooper Companies | 82 | |
| Wayne Wilson | Hologic | 65 | |
| Claire Pomeroy | Becton Dickinson and | 65 | |
| Elisha Finney | ICU Medical | 56 | |
| Raymond Blight | Alcon AG | N/A | |
| Stephen Klasko | Teleflex Incorporated | 67 | |
| Basil Anderson | Becton Dickinson and | 70 | |
| James Orr | Becton Dickinson and | 70 | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.12 |
West Pharmaceutical Leadership Team
Elected by the shareholders, the West Pharmaceutical's board of directors comprises two types of representatives: West Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of West. The board's role is to monitor West Pharmaceutical's management team and ensure that shareholders' interests are well served. West Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, West Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Buthman, Independent Director | ||
| Deborah Tanner, Independent Director | ||
| Bernard Birkett, Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer | ||
| Eric Green, President, Chief Executive Officer, Director | ||
| John Weiland, Independent Director | ||
| William Federici, CFO and Sr. VP | ||
| Rudy Poussot, Senior Development | ||
| Michael Anderson, Vice President Treasurer | ||
| Dr CFA, Vice Relations | ||
| William Feehery, Independent Director | ||
| Robert Friel, Independent Director | ||
| Richard Luzzi, VP HR | ||
| Daniel Malone, Principal Accounting Officer, VP and Controller | ||
| Myla LaiGoldman, Independent Director | ||
| Heino Lennartz, President - Pharmaceutical Packaging Systems Europe Region | ||
| Paula Johnson, Independent Director | ||
| Douglas Michels, Independent Director | ||
| Michele Polinsky, Vice Communications | ||
| Kimberly MacKay, Senior Vice President General Counsel, Corporate Secretary | ||
| Karen Flynn, Senior Vice President and Chief Commercial Officer | ||
| Paolo Pucci, Independent Director | ||
| Annette Favorite, Chief Human Resource Officer, Senior Vice President | ||
| Anthony Welters, Independent Director | ||
| Patrick Zenner, Independent Chairman of the Board | ||
| Thomas Hofmann, Independent Director | ||
| Silji Abraham, Senior Vice President and Chief Digital and Transformation Officer | ||
| David Montecalvo, Senior Vice President, Chief Operating and Supply Chain Officer | ||
| John Paproski, CTO and Sr. VP | ||
| Christopher Ryan, Senior Vice President of Commercial Products and Emerging Markets | ||
| Warwick Bedwell, President of Pharmaceutical Packaging Systems Asia-Pacific Region | ||
| Quintin Lai, Vice President - Corporate Development, Strategy and Investor Relations | ||
| Molly Joseph, Director | ||
| George Miller, Senior Vice President General Counsel, Corporate Secretary | ||
| Cindy ReissClark, Senior Vice President of Global Market Units and Commercial Solutions | ||
| Chad Winters, Chief Accounting Officer, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Robert Segura, VP Devel | ||
| Eric Resnick, Chief Technology Officer, Vice President |
West Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is West Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 28.06 B | ||||
| Shares Outstanding | 73.21 M | ||||
| Shares Owned By Insiders | 0.56 % | ||||
| Shares Owned By Institutions | 95.90 % | ||||
| Number Of Shares Shorted | 1.13 M | ||||
| Price To Earning | 40.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether West Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if West Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about West Pharmaceutical Services Stock. Highlighted below are key reports to facilitate an investment decision about West Pharmaceutical Services Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for West Stock analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is West Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of West Pharmaceutical. If investors know West will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about West Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.334 | Dividend Share 0.77 | Earnings Share 7.88 | Revenue Per Share 39.701 | Quarterly Revenue Growth 0.033 |
The market value of West Pharmaceutical is measured differently than its book value, which is the value of West that is recorded on the company's balance sheet. Investors also form their own opinion of West Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is West Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because West Pharmaceutical's market value can be influenced by many factors that don't directly affect West Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between West Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if West Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, West Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.